Opthea’s Phase 2b Study of OPT-302 in Wet AMD to be Presented in Late-Breaking Session of EURETINA

by NASDAQ Market News September 4, 2019

NASDAQ Market News
Click here to email author

U.S. Defense Reports Immuron’s Travelan® demonstrates broad reactivity to Vibrio cholera strains from Southeast Asia indicating broad potential for prevention of travelers’ diarrhea

Curetis and OpGen Enter Into Definitive Agreement to Combine Businesses

Ads